SignalXSignalX

INVA Innoviva, Inc.

FY2025 10-K
Filed: Feb 25, 2026
Health Care
Pharmaceutical PreparationsSEC EDGAR
Innoviva, Inc. Overview

Innoviva, Inc. (INVA) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Core business: diversified biopharmaceutical company with royalties portfolio plus critical care and infectious disease operating platform (Innoviva Specialty Therapeutics)
  • • New products launched: XACDURO® (2023), ZEVTERA® (Q3 2025), and FDA approval of NUZOLVENCE® (Dec 2025) for infectious diseases
+3 more insights

Management Discussion & Analysis

  • • Revenue details and YoY change not disclosed in provided MD&A excerpt
  • • Profitability or margin data not included in provided text
+3 more insights

Risk Factors

  • • FDA approval of NUZOLVENCE® in Dec 2025, with commercialization planned in H2 2026, regulatory risk around market launch and adoption timing
  • • Pricing pressures in U.S. caused 2% decline in royalty revenue to $236.5M in 2025, signaling macroeconomic risk on revenue from GSK royalty portfolio
+3 more insights

Get deeper insights on Innoviva, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available